First is Professor Antoine Italiano, an internationally renowned medical oncologist specializing in early drug development and precision medicine. He heads the Department of Medicine at the Institut Bergonié (Bordeaux) and leads the precision medicine program at Gustave Roussy (Paris). Notably, he has served as the principal investigator in more than 50 phase I trials and over 40 phase II and III clinical trials in the past five years.

Next is Ignacio Melero, professor of immunology at the University of Navarra in Spain and co-director of the Department of Immunology and Immunotherapy at the Clinica Universidad de Navarra. He is widely recognized internationally for his pioneering work in cancer immunotherapy, particularly on immunostimulatory monoclonal antibodies and the costimulation of antitumor immune responses.

Alessandro Riva, Chairman and CEO of Transgene, stated: "We are honored to have them with us, and we are delighted to work together to accelerate the development of myvac, our individualized therapeutic vaccine platform based on neoantigens. Their contribution will help us achieve the next key milestones in the clinical development of our other viral vector-based cancer vaccine candidates."